AF, Aflutter 09-x (1) Flashcards
AF ectopic location?
pulmonary veins
AF ECG? 3
Irregularly irregular rhythm with varying R-R intervals
No clearly discernible P waves
Narrow-complex tachycardia
AF symptoms?
Palpitations
Weakness/fatigue
Dizziness
Presyncope
Dyspnea
Chest pain/tightness
AF ventricular response?
HR > 150 k/min.
AF. Hemodynamically unstable?
Syncope
Symptomatic hypotension
Acute HF, pulmonary edema
Ongoing myocardial ischemia
Cardiogenic shock
paroxysmal AF?
AF that terminates sponateously OR with intervention within 7 days of onset.
AF that terminates sponateously OR with intervention within 7 days of onset?
paroxysmal AF?
Persistent AF?
AF that is continuously sustained beyond 7 days, including episodes terminated by cardioversion (drug or electrical cardioversion) after >= 7 days.
AF that is continuously sustained beyond 7 days, including episodes terminated by cardioversion (drug or electrical cardioversion) after >= 7 days.
Persistent AF
Long-standing persistent AF?
Continuous AF > 12 months when decided to adopt a rhythm control stategy
Continuous AF > 12 months when decided to adopt a rhythm control stategy
Long-standing persistent AF
Permanent AF?
AF that is accepted by the patient and physician, an no further attempts to restore/maintain sinus rhythm will be undertaken.
AF that is accepted by the patient and physician, an no further attempts to restore/maintain sinus rhythm will be undertaken.
therm should now be used in the context of a rhythm control strategy with antiarrhytmic drug therapy or AF ablation.
Permanent AF
AF DIAGNOSTIC CRITERIA? 2
12-lead ECG recording
OR
single-lead ECG tracing of >=30 s
If fulfills this criteria –> it is CLINICAL AF.
Primary diagnostic workup for AF?
Medical history: AF related symptoms, AF patterns, concomitant conditions, CHA2DS2VAS2 score; 12 lead ECG, Thyroid and kidney function, electrolytes, full blood count, TTE.
AF management abreviation?
ABC pathway
A Anticoagulation/Avoid stroke;
B Better symptom management;
C Cardiovascular and Comorbidity optimization
CHA2DS2-VASc. C?
Congestive heart failure
CHA2DS2-VASc. H?
Hypertension
Also patients on antihypertensive therapy
CHA2DS2-VASc. A2?
Age >= 75
CHA2DS2-VASc. D?
DM
CHA2DS2-VASc. S2?
Stroke/TIA/Thromboembolism
CHA2DS2-VASc. V?
Vascular disease - prior. MI, PAD, aortic plaque, angiographically significant CAD
CHA2DS2-VASc. A?
age 65-74 y/o
CHA2DS2-VASc. Sc?
Sex category - i.e. FEMALE
AF + NO prosthetic valve or mitral stenosis. What is the 1 step?
Identify low risk patients, i.e. Male 0 points, female 1 point.
AF + NO prosthetic valve or mitral stenosis.
If patients is low risk, what anticoagulation?
NO ANTICOAGULATION
AF + NO prosthetic valve or mitral stenosis.
Patient IS NOT LOW RISK.
If patient is intermediate risk? what score and what treatment?
Male >= 1
Female >= 2
OAC should be CONSIDERED (individually)
AF + NO prosthetic valve or mitral stenosis.
Intermediate risk. Which 2 points carries highest tromboembolism risk?
Age 65 to 74 years (pats stipriausias faktorius!!!!) and the presence of heart failure –> GIVE OAC
AF + NO prosthetic valve or mitral stenosis.
Intermediate risk. When OAC not needed?
low burden of AF (eg, AF that is well documented as limited to an isolated episode that may have been due to a reversible cause such as recent surgery, heavy alcohol ingestion, or sleep deprivation
What is recommended for anticoagulation in general?
NOAC > warfarin
AF + NO prosthetic valve or mitral stenosis.
Patient IS HIGH risk. what score and what treatment?
Male >= 2
Female >=3
OAC RECOMMENDED
AF + YES prosthetic valve or mitral stenosis.
treatment?
VKA (warfarin)
INR range depends on type of valve lesion or prosthesis